skip to Main Content
  • Français
  • Deutsch
  • Italiano

BREAST CANCER PREVENTION 30 MINUTES TO  REASSURE YOU  THANKS TO A  PERSONALISED SCREENING  HAVE A MAMMOGRAM EVERY  2 YEARS ?  EVERY  YEARS ?  START AT  50 ?  OR FROM THE AGE OF  40 ?  TOGETHER WITH YOUR DOCTOR, DEFINE  YOUR PROGRAMME  AND BENEFIT FROM  APPROPRIATE RECOMMENDATIONS  MEDICAL
QUESTIONNAIRE
SALIVA
SAMPLING
REVIEW AND
PROGRAMME

Since 2019, Predilife has been marketing MammoRisk®, the first breast cancer risk prediction solution in Europe offering women a clear report for personalised screening.

With your doctor, access recommendations adapted to your profile thanks to a health questionnaire (family history, biopsy history, breast density) and a saliva sample allowing us to analyse your “Polygenic Risk Score”.

You will benefit from a personalised screening in order to do everything possible to detect a possible breast cancer as early as possible and thus protect your health. Complete care, reliable results, a unique follow-up, for an essential serenity.

Today, all women from 40 years of age can request a prevention consultation from their doctor and have their breast cancer risk assessment.

Why follow a personalised screening?

  • To receive recommendations adapted to your level of risk.
  • To confirm that your current screening is the right one.
  • To benefit from increased care if you are “at risk”.
  • To reassure you, take charge of your health, anticipate in order to act.

Where to receive a prevention consultation?

Screening and prevention, what does the press say?

MyPeBS partner

Predilife is a partner of the European MyPEBS study, in charge of the breast cancer risk assessment platform.

The main objective of the randomised MyPeBS (My Personal Breast Screening) study is to compare the current organised screening measures – based on the single criterion of age (except where women are identified as very high risk) – with a new screening strategy offering a type and frequency of tests based on each woman’s risk level.

This project received funding from the European Union as part of the Horizon 2020 research and innovation programme – grant agreement no. 755394

For more information: www.mypebs.eu

#HEALTH BLOG

What is the Polygenic Risk Score?

Definition SNP and polygenic risk score In humans, 99.9% of DNA building blocks are the…

lire la suite
All about breast density

The association between breast density and the risk of breast cancer has been studied and…

lire la suite
Screening at the time of the Covid

For several months now, the whole world has been experiencing an unprecedented health crisis. Between…

lire la suite
What is the difference between breast density, breast size and breast firmness?

For the general public, it is common to confuse breast density with breast size. There…

lire la suite
MammoRisk® is a Class I medical device manufactured by Predilife. It is a regulated health product which carries the CE mark under these regulations. 
Read the user manual carefully before use. MammoRisk® is not a diagnostic test. MammoRisk® is a breast cancer risk assessment test. 
Back To Top